Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL28424110 | 0.97 | HTR2A (0.35) | HTR2AHDAC9POLBL3MBTL1TRPA1 | |
| Methane SCHEMBL29046923 | 0.97 | HTR2A (0.35) | HTR2AHDAC9POLBL3MBTL1TRPA1 | |
| SCHEMBL27498922 | 0.97 | HTR2A (0.35) | HTR2AHDAC9POLBL3MBTL1TRPA1 | |
| SCHEMBL13199764 | 0.84 | ADRA2A (0.41) | TRPA1 | |
| SCHEMBL11147882 | 0.80 | ALDH1A1 (0.40) | — | |
| SCHEMBL11154101 | 0.80 | GAA (0.39) | POLBL3MBTL1GAA | |
| SCHEMBL8707641 | 0.77 | HTR1A (0.40) | HTR2A | |
| SCHEMBL8162156 | 0.77 | HDAC9 (0.39) | HDAC9 | |
| SCHEMBL5917138 | 0.74 | CD44 (0.38) | GAA | |
| SCHEMBL22271488 | 0.74 | ADRA2A (0.39) | TRPA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| EP-4048397-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THERAPEUTIC APPLICATIONS | UNIV MICHIGAN REGENTS (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4048397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Regents Of The University Of Michigan (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220169580-A1 | METHODS OF CARBON-CARBON BOND FRAGMENTATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-02 | — | — | US | disclosed |
| US-11312726-B2 | Thienodiazepine derivatives and application thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-04-26 | — | — | US | disclosed |
| US-11220479-B2 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210122712-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2021-04-29 | — | — | US | disclosed |
| WO-2021081141-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20210017190-A1 | THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
| EP-3686204-A1 | THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| WO-1994028034-A1 | SUPPORTED METALLOCENE CATALYST SYSTEMS FOR THE POLYMERIZATION OF OLEFINS, PREPARATION AND USE THEREOF | EXXON CHEMICAL PATENTS INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| US-5276208-A | Catalysts for polymerization of olefins | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-01-04 | — | — | US | disclosed |
| EP-0563818-A2 | High rigidity and high hardness polyolefin composition | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-10-06 | — | — | EP | disclosed |
| US-5243001-A | Alunimoxane and metallocene catalysts | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-09-07 | — | — | US | disclosed |
| US-5239022-A | Using aluminoxane and metallocene catalyst | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-24 | — | — | US | disclosed |
| US-5145819-A | 2-SUBSTITUTED DISINDENYLMETALLOCENES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS CATALYSTS IN THE POLYMERIZATION OF OLEFINS | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-09-08 | — | — | US | disclosed |
| EP-0485820-A2 | Process for preparing olefin polymers | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-05-20 | — | — | EP | disclosed |
| EP-0485823-A1 | 2-Substituted bisindenyl-metallocenes, process for their preparation and their use as catalysts for the polymerization of olefins | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-05-20 | — | — | EP | disclosed |
| EP-0485821-A1 | Metallocenes with 2-substituted indenyl-derivates as ligands, process for their preparation and their use as catalysts | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-05-20 | — | — | EP | disclosed |
| EP-0485822-A2 | Process for preparing high molecular weight polyolefines | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017190-A1 | THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF | BRD4, BRD3, BRD2 | HTR2A 525/4885HDAC9 36/4885POLB 2257/4885 |
| US-20220169580-A1 | METHODS OF CARBON-CARBON BOND FRAGMENTATION | CYCS, COX6C, COXFA4L2 | HTR2A 4430/4885HDAC9 4098/4885POLB 336/4885 |
| US-11220479-B2 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | GBA1, GBA2, GAA | HTR2A 4723/4885HDAC9 824/4885POLB 1087/4885 |
| US-11312726-B2 | Thienodiazepine derivatives and application thereof | BRD4, BRD3, BRD2 | HTR2A 525/4885HDAC9 36/4885POLB 2257/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | HTR2A 3936/4885HDAC9 194/4885POLB 1369/4885 |
| US-20210122712-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | GBA1, GBA2, GAA | HTR2A 4723/4885HDAC9 824/4885POLB 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.